gabriel-baertschi

Grünenthal chief executive Eric-Paul Pâques to retire; new CEO named

pharmafile | June 7, 2016 | Appointment | |  CEO, Grünenthal Group, appointment 

Germany-based Grünenthal Group on Tuesday named Gabriel Baertschi its chief executive officer effective October 1, 2016. 

He succeeds Eric-Paul Pâques who will retire at the end of 2016 after 23 years with the family-owned company.

Baertschi will join from AstraZeneca (LSE: AZN) where he currently serves as president for Japan. 

Advertisement

Gabriel Baertschi said: “I am honored to have been elected as Grünenthal’s CEO. It is a privilege to be part of an organization that delivers high quality products and innovative solutions to the patients. Grünenthal is an organization led by a purpose: to bring true benefits to patients by being an entrepreneurial specialist. I am deeply committed to building long-term value for patients, clinicians, and our partners together with a very experienced team at Grünenthal.”

 

Related Content

David Wheadon appointed to board of directors at Seaport Therapeutics

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

5997920696_ecb224068e_b

CEO of PixarBio Corporation sentenced to prison for defrauding investors

Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

The Gateway to Local Adoption Series

Latest content